Wasatch Micro Cap Fund Q2 2026 Contributors And Detractors

TriSalus posted a significant revenue miss and lowered guidance, attributing the weakness to a Salesforce reorganization and a delayed FDA review of its next-generation device. In contrast, Suncrete’s shares moved higher after strong first-quarter revenue growth, but the broader read-through is cautious given the regulatory delay and guidance cut at TriSalus.

Analysis

AMBQ looks like the only constructive signal here, but the market should treat it as a company-specific proof point rather than a clean read on semis. For a recent IPO, strong growth in an ultra-low-power niche can justify a faster multiple expansion than the broader chip group because it speaks to design-win durability in battery-constrained edge use cases; the second-order benefit is to other differentiated names where power efficiency is the real product moat. That said, post-IPO enthusiasm is fragile: if sequential growth or gross margin does not keep up, the premium can compress just as fast as it expanded.

The downside is more about execution fragility than any single quarter number. A sales-org disruption paired with a regulatory delay tends to hit revenue timing and cash conversion together, which is especially painful for smaller medtech names with limited financing flexibility and high fixed SG&A. For CRM, the read-through is more subtle: if a large platform is reorganizing, it can signal slower sales-cycle conversion and budget churn across adjacent SaaS, but this becomes tradable only if it persists into the next guidance cycle.

The contrarian view is that the bad news may be mostly timing while the good news may need confirmation. A clean regulatory restart or evidence that the sales disruption was temporary would unwind the negative move quickly, so the near-term reaction can overstate the medium-term fundamental damage. Falsifiers to watch: AMBQ next-quarter sequential revenue and gross margin, and any renewed guidance cut or regulatory slippage from the medtech side; absent those, this is more of a volatility event than a structural thesis change.

Key Decisions for Investors

• Long AMBQ on post-earnings pullbacks over the next 1-2 weeks; target a 15-20% re-rating over 1-2 months if sequential growth holds and margin does not compress. Cut the trade if next quarter guide or gross margin disappoints.
• Avoid chasing the weak medtech print until there is evidence the FDA delay is temporary; if a filing/resubmission date is announced, that is the point to reassess for a 1-3 month rebound rather than sell the first bounce.
• Use any CRM strength over the next 2-6 weeks to fade the move only if management commentary confirms sales-organization disruption is still affecting pipeline conversion; otherwise keep CRM on the watch list, not as a high-conviction short.
• Relative-value idea: small long AMBQ / small short CRM as a tactical pair only if market is rewarding differentiated growth and punishing execution noise; keep size modest because the correlation is weak and the trade is event-driven, not structural.